Denosumab, a fully humanized monoclonal antibody against RANKL—initially developed for the treatment of osteoporosis—proved effective in RA patients, positively influencing erosions and BMD—even in patients concurrently receiving glucocorticoids—more than 10 years ago [87]. The gene discussed is TNFSF11; the disease is osteoporosis.